Properties
What is it?
International Nonproprietary Name - nifuroxazide Clinical-pharmacological group - Antidiarrheal preparations; Local-acting antimicrobial preparations Composition Each 5 ml of suspension contains: 200.0 mg nifuroxazide Excipients: Sucrose, Ethanol 96%, Carbomer, Methylparahydroxybenzoate, Sodium hydroxide, Citric acid anhydrous, Banana flavor, Purified water. Indications - Diarrhea in children and adults caused by alimentary infections and intoxications, particularly those caused by E. coli; - Chronic diarrhea during colitis; - Intestinal fermentation disorder; - Acute and chronic diarrhea of non-specific and undetermined etiology without invasive phenomena; - Iatrogenic diarrhea caused by antibiotic intake; - Symptomatic diarrhea in case of colon cancer; - Some forms of acute attacks of infectious hemorrhagic rectocolitis; - Prevention of traveler's diarrhea. Dosage and Administration A 5-ml dosing spoon, divided into 2.5 ml, is used for dosing. Shake the suspension well before use. Children from 6 months to 2 years: 2.5 ml 3 times a day. Children from 3 to 7 years: 5 ml 3 times a day. Therapy with nifuroxazide can only be continued for 7 days. Contraindications - Allergy to nitrofurans and/or excipients of the preparation; - Infants under 6 months of age. Adverse Effects Nifuroxazide is characterized by good tolerability. Very rarely, it can cause sensitization and allergic reactions. Pregnancy and Lactation There is no data on whether nifuroxazide intake during pregnancy causes possible adverse effects on the fetus. Nifuroxazide is not absorbed from the gastrointestinal tract. Therefore, there is no possibility of its excretion into breast milk. Accordingly, the preparation can be used during lactation. Special Instructions Alcohol consumption is strictly prohibited during treatment. When treating diarrhea with nifuroxazide, rehydration (oral or intravenous) is necessary along with therapy, taking into account the patient's condition and the intensity of diarrhea. Not to be used in patients with fructose intolerance, malabsorption syndrome, and sucrose-isomaltase deficiency. Effect on ability to drive and operate machinery. The preparation does not affect the patient's ability to drive vehicles and operate machinery.